SFDA Medical Device Registration (MDMA) in Saudi Arabia: Classes, Authorized Representative, Fees and Timelines

If you want to sell a medical device in Saudi Arabia, there is exactly one legal gate: a Medical Device Marketing Authorization (MDMA) issued by the Saudi Food & Drug Authority (SFDA). No MDMA, no customs clearance, no hospital purchase order, no NUPCO tender. This guide explains what the process actually involves, what it costs, how long it realistically takes, and where foreign manufacturers most often lose months.

1. Who needs an MDMA, and what counts as a medical device

Any product that meets the SFDA's definition of a medical device or in-vitro diagnostic (IVD) needs an MDMA before it can be imported, distributed, or used in the Kingdom. The definition is broad and closely mirrors the IMDRF/GHTF framework: instruments, implants, software, reagents, and accessories intended for diagnosis, monitoring, treatment, or alleviation of disease. Products that sit on the borderline (aesthetic devices, wellness products, certain cosmetics with medical claims, disinfectants) are a frequent source of misclassification and delay. If you are not sure whether your product is a device in SFDA's eyes, resolve that question before anything else.

2. Risk classification: Class A to D

Saudi Arabia uses a four-tier, risk-based system that maps closely to the EU MDR:

IVDs follow a parallel A-to-D scheme based on the risk of an incorrect result to the patient and to public health.

Your class determines the fee, the depth of technical review, and the level of clinical evidence expected. Choosing the wrong class is one of the most common causes of rejection: too low and SFDA returns the file; too high and you pay more and wait longer than necessary.

3. The Authorized Representative: the decision that matters most

A manufacturer with no legal entity in Saudi Arabia cannot apply to SFDA directly. You must appoint a Saudi-resident Authorized Representative (AR) that holds an annually renewable AR Licence issued through SFDA's GHAD electronic system. The AR submits your application, holds your technical file, authorizes imports, and manages post-market obligations on your behalf.

Three things every manufacturer should understand before signing an AR agreement:

The MDMA belongs to you, not to the AR. The AR holds the authorization on behalf of the manufacturer. You can change AR without the outgoing AR's consent; SFDA processes the transfer through GHAD and existing certificates carry over without re-registration fees. Manufacturers who believe they are "locked in" usually are not.

Your distributor does not have to be your AR. In practice many distributors offer to act as AR because it strengthens their commercial position. That can work well with the right partner, but it also concentrates regulatory and commercial control in one hand. Many manufacturers prefer an independent AR so that a distributor change never becomes a regulatory event.

One AR per device group. You cannot split a single product family across two ARs at the same time. Plan your grouping before you plan your distribution.

The AR Licence fee is modest (SAR 2,600 per year at the time of writing); the AR's commercial service fee is negotiated separately.

4. The MDMA pathway step by step

1. Appoint an Authorized Representative and execute an authenticated AR agreement.
2. Confirm classification and decide grouping. One application can cover a device family, system, or procedure kit when the items share the same manufacturer, risk class, and intended use (up to 50 items per application under current rules).
3. Assemble the technical file in the format SFDA expects. The core contents are: device description and intended purpose; labelling and instructions for use; risk management file (ISO 14971); design and manufacturing information; verification and validation data; pre-clinical and clinical evidence proportionate to class; Declaration of Conformity; post-market surveillance plan; and your quality system certificate (ISO 13485:2016).
4. Add the commercial and legal documents: proof of the manufacturer's legal status, existing approvals in other markets (CE certificate, FDA clearance or approval, MDSAP, etc.), and the AR agreement.
5. Submit through GHAD and pay the fee. SFDA issues queries through the system; the clock pauses while you respond.
6. Receive the MDMA. It is valid for three years and can be renewed up to 180 days before expiry.

A prior approval in a reference country is not a formal prerequisite under the current Saudi route, but existing approvals are requested as part of the file and materially shorten the review of your technical documentation.

5. Fees and timelines

SFDA schedule as published; all fees exclude 15% VAT.

Two realistic caveats. First, 35 working days is SFDA's target for a complete file, not a guarantee. Each round of queries adds two to six weeks. A well-prepared Class B or C file typically takes three to five months from submission to certificate; a Class D file with clinical questions can take longer. Second, budget beyond the SFDA fee: AR licence and service fees, document legalisation, Arabic translation of labelling and IFU, and, for some products, sample testing.

6. After the MDMA: getting the product into the country

Registration is the licence to sell; it is not yet the licence to import. Three further pieces are needed:

• Importer / distributor establishment licence (MDEL). Any Saudi company that imports, distributes, or stores medical devices must hold its own SFDA establishment licence. If your distributor does not have one, nothing moves.
• Import authorization issued per shipment through GHAD, referencing the MDMA.
• Customs clearance (فسح). SFDA inspects at the port against the MDMA, labelling, and shelf-life requirements.

There is also a narrow exception worth knowing: Saudi hospitals can, in defined circumstances, obtain direct clearance (فسح مباشر) for an unregistered device for a specific clinical need. This is not a substitute for registration, but it can support an early clinical evaluation or an urgent institutional purchase while your MDMA is in progress. We cover these routes in a separate article.

7. Where foreign manufacturers lose months

From our own work on registrations and institutional supply in the Kingdom, these are the recurring causes of delay:

1. Misclassification — especially for aesthetic, regenerative, and borderline products.
2. Name mismatches — the manufacturer's legal name and address differ between the ISO certificate, the CE certificate, the Free Sale Certificate, and the labelling. SFDA reads every document literally.
3. Arabic labelling and IFU — missing, machine-translated, or inconsistent with the English version.
4. Expired or un-legalised certificates — Free Sale Certificates and manufacturer declarations that are out of date or not attested.
5. Outdated standards — technical files citing superseded versions of ISO 13485, ISO 14971, or IEC 60601.
6. Unanswered system questions — GHAD asks specific questions about storage, tracking (UDI), and distribution; leaving them incomplete stalls the file.
7. Starting an AR transfer while an application is under review — this freezes the application. Settle your AR arrangement before you submit.
8. Registering before the commercial plan exists — an MDMA with no licensed distributor, no hospital champion, and no tender strategy is a certificate on a wall. Registration and commercial entry should be planned together.

8. Frequently asked questions

Can I register without a Saudi distributor?

Yes. You need an Authorized Representative, not a distributor. Many manufacturers register first and select distributors afterwards, from a position of strength.

Does a CE mark or FDA clearance exempt me from anything?

No. It supports your technical file and speeds the review, but SFDA conducts its own assessment and issues its own authorization.

How long is the MDMA valid?

Three years, renewable.

Do I need separate registrations for Saudi Arabia and the other GCC states?

Yes. Each Gulf regulator issues its own authorization, although a Saudi MDMA is well regarded across the region and often simplifies the others.

Is NUPCO registration part of the SFDA process?

No. NUPCO is the public-sector procurement company, not a regulator. NUPCO vendor qualification comes after, and requires, a valid MDMA and a licensed local partner.

Related reading: How NUPCO Tenders Actually Work · The GCC Market-Entry Checklist

Sources: SFDA Medical Device Marketing Authorization fee schedule (MDMA-Fee, 2025); SFDA GHAD system guidance; SFDA requirements for Authorized Representatives. Figures verified 16 September 2026. This article is general guidance and not a substitute for regulatory advice on a specific product.